

Research Paper

Development and validation of a prediction model for recurrence based on ProMisE molecular classifier and immune-inflammatory- nutritional score in endometrial carcinoma: a retrospective multiple-center study

Yunfeng Zheng¹, Fan Yang⁴, Gaohua Liu⁵, Xixi Wu⁶, Langting Xie^{7,8}, Ran Hu², Xiaoxiao Luo^{3✉}, Rui Yuan^{2✉}

1. Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases, Hangzhou, Zhejiang, China.
2. Department of Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
3. Department of Obstetrics and Gynecology, Renji Hospital, School of Medicine, Chongqing University, Chongqing, China; The Fifth People's Hospital of Chongqing, Chongqing, China.
4. Cancer Center, Department of Ultrasound Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China.
5. Institute of Clinical Medicine, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
6. Department of Gynecology, Chengdu Women's and Children's Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
7. Department of Gynecology and obstetrics, Fujian Provincial Maternity and Children's Hospital, Fuzhou, Fujian, China.
8. Department of Gynecology and obstetrics, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.

✉ Corresponding authors: Rui Yuan, MD, Department of Gynecology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. E-mail: yruy96@hospital.cqmu.edu.cn. Tel: +86 023-68486646. Xiaoxiao Luo, M.D., Department of Gynecology and Obstetrics, Renji Hospital, School of Medicine, Chongqing University, The Fifth People's Hospital of Chongqing, Chongqing, China. Email: 494262191@qq.com. Tel: +86 023-62896109.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>). See <https://ivyspring.com/terms> for full terms and conditions.

Received: 2024.11.08; Accepted: 2025.04.08; Published: 2025.08.16

Abstract

Objective: This study aims to develop a robust prediction model using the ProMisE molecular classification and the prognostic immune-inflammatory-nutritional score to predict recurrence in stage I-III endometrial cancer, thereby enabling risk stratification of high-risk patients.

Methods: The clinical data of 582 patients (365 in the training cohort and 217 in the validation cohort) were collected from multiple large cancer centers from patients with stage I-III endometrial cancer who underwent surgical resection between August 2019 and February 2022. Cox proportional hazards regression analysis was used to identify the risk factors for recurrence-free survival (RFS). The concordance index (C-index), area under the receiver operating characteristic (ROC) curves, calibration plots, and decision curve analyses (DCA) were used to assess discrimination and clinical utility of the model.

Results: Patients with a hemoglobin, albumin, lymphocyte, and platelet (HALP) score ≤ 31.70 tended to have lower BMI ($P = 0.017$), advanced FIGO stage ($P = 0.016$), deep myometrial invasion ($P < 0.001$), and higher serum Ca125 levels ($P < 0.001$). Multivariate Cox regression analysis showed that age, FIGO stage, grade, LVSI, Ca125, ProMisE molecular subgroup, HALP score, and adjuvant therapy were independent prognostic factors for RFS in patients with endometrial cancer. A nomogram for predicting RFS was established, and patients were stratified into high- and low-risk groups based on the RFS model.

Conclusions: The preoperative HALP score serves as a reliable predictor of RFS in endometrial cancer. A nomogram combining the HALP score, ProMisE molecular subtyping, and clinical parameters can assist clinicians in identifying high-risk patients for recurrence. These patients may benefit from early triage and more intensive monitoring.

Keywords: endometrial carcinoma, molecular classifications, nomogram, HALP score, recurrence-free survival, risk stratification

Introduction

Endometrial cancer is the most common gynecologic malignancy, with increasing global incidence and mortality rates [1]. According to GLOBOCAN 2020 data from the International Agency for Research on Cancer, there were an estimated 63,246 newly diagnosed cases of endometrial cancer and 11,909 cancer-related fatalities in the United States [2]. In China, approximately 84,520 new cancer cases and 17,543 cancer deaths are reported annually, posing a serious threat to women's health [3]. The majority of patients with endometrial cancer are initially diagnosed with low-grade and early-stage disease, with a favorable prognosis that can be cured through complete surgery alone [4]. However, approximately 20% of patients present at an advanced stage or are at high risk of recurrence, significantly contributes to cancer-related deaths [5, 6]. Effectively identifying individuals at high risk of recurrence to inform them of their prognosis, perform appropriate surgeries, and administer the best adjuvant therapies to improve their outcomes remains the greatest challenge.

In 1983, Bokhman classified endometrial cancer into type I (estrogen-dependent) and type II (non-estrogen-dependent) based on its clinical and pathological characteristics [7]. With the advancement of cancer-related research, the diagnosis and treatment of endometrial cancer are no longer confined to the traditional field of histopathology. The exploration of more precise molecular and immune-inflammatory-nutritional markers for precision therapy has emerged as a prominent focus of current research. The Cancer Genome Atlas (TCGA) molecular classification of endometrial cancer integrates genomic, transcriptomic, proteomic, gene copy number, and methylation data, categorizing endometrial cancer into four subtypes: *POLE* ultra-mutated (*POLE*-mut), microsatellite instability-high (MSI-H), copy number low (CN-L), and copy number high (CN-H) [8]. These molecular subgroups, with significant prognostic differences, have been widely validated as effective biomarkers and have been incorporated into the latest guidelines. Due to the requirement for integrating data from multiple platforms and omics disciplines, the clinical application of this molecular classification strategy is quite complex, which limits its widespread adoption in some developing countries or underdeveloped regions. Subsequently, some scholars have further improved and simplified the detection methods and processes for this molecular classification, proposing strategies such as TransPORTEC [9] and ProMisE [10], which have been clinically validated as accurate and

effective. These molecular classifications are primarily based on techniques such as immunohistochemistry (IHC) and next-generation sequencing (NGS). These strategies not only simplify the operational and detection processes but also ensure their consistency with the TCGA molecular classification. These clinically relevant molecular subgroups have been replicated using surrogate markers in IHC, identifying equivalent subgroups: p53 abnormalities (p53-abn), *POLE* exonuclease domain mutations (*POLE* EDM), mismatch repair deficiency (MMR-D), and p53 wild-type (p53wt). Integrating this molecular classification with established clinicopathological data has led to an updated risk classification system for determining the relative risk of recurrence.

Emerging evidence demonstrates a significant correlation between systemic inflammation, malnutrition, and the clinical outcomes of cancer patients [11, 12]. Several immune-inflammation indices and nutritional scores (i.e. systemic immune-inflammation index [13, 14], neutrophil-to-lymphocyte ratio [15, 16], and prognostic nutritional index [17]) have been confirmed as effective biomarkers for prognostic evaluation in various cancers. However, these indicators typically capture only a fraction of the individual's overall status, and the clinical prognosis is often influenced by a variety of complex factors. This underscores the importance of a comprehensive evaluation that encompasses various factors, including systemic inflammation, nutritional status, and immune function. The hemoglobin-albumin-lymphocyte-platelet (HALP) score, as a comprehensive index, effectively reflects the systemic inflammatory response, nutritional status, and immune status. It is utilized to evaluate treatment efficacy and predict the survival outcomes of cancer patients [18, 19]. Although the clinical value of molecular classification and the HALP score has been widely recognized and integrated into clinical practice, this classification strategy is still in its early stages in China, especially in the field of endometrial cancer, where widely accepted identification and classification standards have not yet been established. For patients with recurrence or those in advanced stages, combining molecular subtyping with the HALP score for risk assessment and identifying high-risk recurrence populations is of significant clinical importance.

Therefore, we conducted this study across multiple Chinese medical institutions to investigate the value of the HALP score and ProMisE molecular classification in predicting the prognosis of patients with endometrial cancer. A prognostic nomogram was established to assist clinicians in accurately estimating the prognosis.

Material and Methods

Patient population

Between August 2019 and February 2022, a total of 582 patients with stage I-III endometrial cancer who were treated at multiple Chinese institutions with surgical resection, with or without radiotherapy and chemotherapy, were retrospectively included. Patients who received radiochemotherapy (RChT) prior to surgery and those with incomplete clinicopathological information were excluded from the analysis. Additionally, patients who had concurrent other cancers were also excluded. Details on the inclusion and exclusion criteria, as well as the flowchart of this study, are provided in Figure 1.

Surgical procedures and postoperative adjuvant treatment

For treatment, all endometrial cancer patients underwent a surgical staging procedure, including total hysterectomy, bilateral salpingo-oophorectomy, and lymph node staging (sentinel lymph node \pm pelvic lymph node \pm para-aortic lymphadenectomy). Based on comprehensive surgery and pathological staging, radiotherapy was administered within 12 weeks post-operatively, consisting of vaginal brachytherapy (range: 22.0-24.0 Gy, administered in 4 fractions of 5.5-6.0 Gy) and/or pelvic external beam radiotherapy (range: 45.0-50.0 Gy, administered in 25 fractions of 1.8-2.0 Gy) [20]. Platinum-based chemotherapy was administered every 3 weeks for 6-8 cycles, either concomitantly or following radiotherapy, based on the assessment by the medical oncologist, considering comorbidities and patient performance status [20].

Outcomes

The primary endpoint of the study was recurrence-free survival (RFS). All time-to-event data were censored at the last follow-up if the corresponding event had not occurred. All patients who underwent complete staging surgery with lymph node dissection received regular follow-up. Data from patients without recurrence at the last follow-up (August 12, 2024) were censored.

DNA extraction and sequencing

For specific methods on DNA extraction and sequencing for polymerase epsilon exonuclease domain mutations, please refer to these studies [10, 21]. For more information, please consult the previous important research [22, 23].

HALP score construction and variables

Clinical pathological and follow-up data were

systematically gathered by trained assistants using standardized data collection forms, and subsequently verified by a senior physician. Blood test results obtained within one week before the operation were collected, including hemoglobin level, albumin level, lymphocyte count, and platelet count. These blood tests were performed using XE5000 and XE-2100 blood cell counters and reagents (SMK). The HALP value was calculated from the routine blood test results of hemoglobin, albumin, lymphocytes, and platelets ($\text{HALP} = \text{hemoglobin [g/L]} \times \text{albumin [g/L]} \times \text{lymphocytes [1/L]} / \text{platelets [1/L]}$) [18].

Clinicopathological data encompassed patient age, tumor grade (categorized as grade 1/2 or grade 3), FIGO stage (classified as stage I to III), histological type (categorized as endometrioid carcinoma or non-endometrioid carcinoma), depth of myometrial invasion (categorized as $\leq 1/2$ or $> 1/2$), LVSI (categorized as negative or positive LVSI), and ProMisE molecular classification (classified as p53wt, MMR-D, *POLE* EDM, and p53abn). A small proportion of patients harbored multiple molecular features, such as both a *POLE* EDM and p53abn, or MMR-D along with p53abn. However, the ProMisE decision tree determines the sequence for assigning tumors to a specific molecular subtype, categorizing the former example as *POLE*-mut and the latter as MMR-D (Figure 2).

Statistical Analysis

Continuous variables were expressed as mean \pm standard deviation and compared using Student's t-tests (for comparing the means of two continuous variables); categorical variables were presented as frequencies and percentages, and their associations were analyzed using Chi-square (χ^2) tests or Fisher's exact test. Kaplan-Meier analysis was performed to estimate the survival rates of RFS, and further compared with Mantel-Cox (log-rank) tests. Multiple prognostic factors were collected and included, and identified as independent prognostic factor based on the Cox proportional hazards model. To enhance the reliability of the nomogram, internal validation was conducted using bootstrapping with 1,000 resamples. The model's predictive performance was evaluated through Harrell's concordance index. Additionally, an external independent cohort was utilized to further validate the predictive model. Calibration curves were generated to assess the model's calibration accuracy. Furthermore, decision curve analysis was conducted to measure net benefits at different probability thresholds, offering insights into the nomogram model's clinical utility. Detailed R code is provided in Supplementary Materials R.





Figure 1. Flow chart for stage I-III endometrial cancer patient inclusion.

ProMisE algorithm



HALP score algorithm

$$\text{HALP score of patients with endometrial cancer} = \text{Hemoglobin (g/L)} * \text{Albumin (g/L)} * \text{Lymphocytes (/L)} \div \text{Platelets (/L)}$$

Figure 2. Identification of ProMisE molecular subtypes and calculation of HALP score. Note: ProMisE algorithm: initially, the IHC of MMR proteins (MLH1, MSH2, MSH6, and PMS2) was evaluated, with adequate positive staining in inflammatory cells or stroma as a reference. Complete absence of MMR proteins staining in tumor cell nuclei was regarded as loss of expression, and the absence of any MMR proteins was defined as MMR deficiency (MMR-D); if the MMR proteins were complete expression (MMR intact), further sequencing of tumors was conducted to identify exonuclease domain mutations in *POLE* gene. Mutations in the exonuclease domain of *POLE* were classified as *POLE* EDM (corresponding to the *POLE* ultra-mutated subtype); otherwise, p53 immunostaining should be performed, with complete negativity staining (null) or strong/diffuse staining in > 70% of cells indicated as p53 abnormal (aberrant positive expression, p53-abn), while other staining patterns are classified as wild type (p53-wt). HALP score algorithm: HALP score = hemoglobin [g/L] x albumin [g/L] x lymphocytes [/L]/platelets [/L].

All statistical analysis were done using SPSS statistical software (version 21.0, Chicago, IL, USA) and R studio (version 1.2.5019). And the *P*-value of less than 0.05 was considered to indicate statistical significance.

Results

Characteristics of the study population

A total of 674 patients with endometrial cancer were included in this study. After excluding 92 patients due to missing and/or uninterpretable follow-up data or clinicopathological data, 582 patients remained for the analysis. Baseline characteristics are presented in Table 1. In the entire study cohort, the mean age of the endometrial cancer patients was 54.26 ± 9.719 years, with a mean BMI of 24.10 ± 3.515 kg/m². Additionally, 84.9% of the patients were diagnosed with endometrioid endometrial carcinoma, followed by non-endometrioid endometrial carcinoma (15.1%). Most patients (66.8%) had negative LVSI, and lower serum Ca125 levels (74.1%). In terms of ProMisE molecular classification, 257 (44.2%) patients harbored p53wt, 148 (25.4%) had MMR-D, 118 (20.3%) had p53abn, and only 59 (10.1%)

had *POLE* EDM. The RFS time for the entire cohort was 36.22 ± 9.964 months. Patients in two cohorts had similar clinicopathological features (*P* > 0.05).

Correlation between HALP score and clinicopathological variables

HALP, as an important indicator reflecting patients' inflammatory, immune, and nutritional status, is closely associated with the prognosis of endometrial cancer patients. The preoperative blood test results obtained within one week before the surgery were collected and are provided in Table S1. In the patient cohort for the present study, we used X-tile software to analyze and determine that the optimal cutoff value of HALP score for predicting recurrence of endometrial cancer is 31.70 (Figure S1). Based on the definition of the cutoff value, the HALP group was divided into a high-HALP group (HALP score > 31.70) and a low-HALP group (HALP score ≤ 31.70). Significant differences in RFS were observed in terms of HALP score, and a low HALP score significantly predicted the dismal RFS in endometrial cancer patients (*P* < 0.001, Figure S2). Additionally, it was found that a lower HALP was significantly correlated with a lower BMI (*P* = 0.017), advanced

FIGO stage ($P = 0.016$), deep myometrial invasion ($P < 0.001$), and higher serum Ca125 ($P < 0.001$), but showed no correlation with other clinicopathological variables in the training cohort, which was similar to the external validation cohort (Table 2).

Establishment of nomogram

Univariate and multivariate Cox regression analyses were performed to identify independent prognostic factors. The eight predictors identified by the multivariate regression model were further recruited and used to develop the RFS nomogram, including age [hazard ratio (HR) 1.820, 95% confidence interval (CI) 1.005-3.293], FIGO stage (HR 2.309, 95% CI 1.033-5.164), tumor grade (HR 2.329, 95% CI 1.082-5.016), LVSI (HR 2.304, 95% CI 1.022-5.195), Ca125 (HR 2.100, 95% CI 1.135-3.885), ProMisE molecular classification (HR 2.551, 95% CI 1.093-5.954), HALP score (HR 2.099, 95% CI 1.182-3.728), and adjuvant treatment (HR 0.352, 95% CI 0.160-0.774) (all $P < 0.05$, Table 3). Based on the degree of contribution of each predictor to the resulting events (RFS), corresponding points (the first axis) were determined. Subsequently, the points of each predictor were aggregated to predict the RFS probability of endometrial cancer patients in stage I-III (Figure 3A and Table S2).

Internal and external validation of nomogram

The established nomogram model was further verified using C-index and AUC values (Figure 3B, C). The nomogram for predicting RFS in the training cohort had a C-index of 0.875 (95% CI 0.836-0.914), and the C-index remained stable in the external validation cohort [C-index of 0.859 (95% CI 0.806-0.912)]. The calibration curves in the training and validation cohorts closely aligned with the ideal line, showing adequate agreement between the predictive nomogram and actual observations (Figure 4).

Comprehensive evaluation of a novel nomogram model for predicting RFS in endometrial cancer

According to DCA curves, the value of the established model in clinical practice has been thoroughly evaluated over time (Figure 5). The results indicate that in both the training and validation cohorts, the threshold probabilities for the standardized net benefit of the predictive model are significantly higher than those of individual variables (such as FIGO stage or ProMisE molecular classification).

Additionally, the differences in C-index were calculated to compare the accuracy of the nomogram

with the FIGO criteria-based tumor staging and ProMisE molecular classifier. These results indicate that the novel nomogram demonstrates a higher prognostic power for RFS in endometrial cancer compared to the FIGO staging system and the ProMisE molecular classification (Table S3). Furthermore, when comparing the nomogram model with other risk stratification systems, the results show that our model provides more accurate predictions for RFS in endometrial cancer (Table 4).

Table 1. Demographic, clinicopathologic, and treatment variables in patients with stage I-III endometrial cancer

Admission variables	Total (n = 582)	Training cohort (n = 365)	External validation cohort (n = 217)	P value
Age, years	54.26 ± 9.719	54.20 ± 9.781	54.36 ± 9.637	0.844
BMI, kg/m ²	24.10 ± 3.515	24.12 ± 3.594	24.07 ± 3.387	0.887
FIGO stage				0.936
I	367 (63.0)	230 (63.0)	137 (63.1)	
II	72 (12.4)	44 (12.1)	28 (12.9)	
III	143 (24.6)	91 (24.9)	52 (24.0)	
Present of LVSI				0.462
Negative	389 (66.8)	248 (67.9)	141 (65.0)	
Positive	193 (33.2)	117 (32.1)	76 (35.0)	
Myometrial invasion				0.589
< 50%	372 (63.9)	229 (62.7)	143 (65.9)	
≥ 50%	210 (36.1)	136 (37.3)	74 (34.1)	
Tumor grade				0.430
G1-G2	451 (77.5)	279 (76.4)	172 (79.3)	
G3	131 (22.5)	86 (23.6)	45 (20.7)	
Histology				0.776
Endometrioid	494 (84.9)	311 (85.2)	183 (84.3)	
Non-Endometrioid	88 (15.1)	54 (14.8)	34 (15.7)	
Serum Ca125				0.740
≤ 35 U/ml	431 (74.1)	272 (74.5)	159 (73.3)	
> 35 U/ml	151 (25.9)	93 (25.5)	58 (26.7)	
ProMisE molecular				0.600
p53wt	257 (44.2)	155 (42.5)	102 (47.0)	
MMR-D	148 (25.4)	94 (25.8)	54 (24.9)	
POLE EDM	59 (10.1)	41 (11.2)	18 (8.3)	
p53-abn	118 (20.3)	75 (20.5)	43 (19.8)	
HALP score				0.510
High-HALP	364 (62.5)	232 (63.6)	132 (60.8)	
Low-HALP	218 (37.5)	133 (36.4)	85 (39.2)	
Adjuvant treatment				0.325
Follow-up	193 (33.2)	122 (33.4)	71 (32.7)	
Radiotherapy only	169 (29.0)	111 (30.4)	58 (26.7)	
Chemotherapy only	20 (3.4)	9 (2.5)	11 (5.1)	
Radio-chemotherapy	200 (34.4)	123 (33.7)	77 (35.5)	
Recurrence				0.690
No	490 (84.2)	309 (84.7)	181 (83.4)	
Yes	92 (15.8)	56 (15.3)	36 (16.6)	
RFS time, month	36.22 ± 9.964	35.58 ± 9.266	37.29 ± 10.979	0.056

Abbreviations: LVSI, lymphovascular space invasion; G1-G2, grade 1/2; G3, grade 3; HALP, hemoglobin-albumin-lymphocyte-platelet; POLE EDM, POLE exonuclease domain mutation; p53-wt, p53 wide-type; p53-abn, p53-abnormal; MMR-D, identifying defective expression of any mismatch repair protein by IHC (i.e. dMMR).

Table 2. Comparison of clinicopathological parameters between the high-HALP group and the low-HALP group (n = 582)

Admission variables	Training cohort		P value	Validation cohort		P value
	Low-HALP	High-HALP		Low-HALP	High-HALP	
Age, years	54.21 ± 10.574	54.24 ± 9.923	0.979	53.04 ± 8.930	55.22 ± 10.006	0.103
BMI, kg/m ²	23.53 ± 3.48	24.46 ± 3.62	0.017	23.51 ± 3.059	24.44 ± 3.536	0.048
FIGO stage			0.016			0.049
I	72 (54.1)	158 (68.1)		47 (54.6)	90 (68.7)	
II	17 (12.8)	27 (11.6)		11 (12.8)	17 (13.0)	
III	44 (33.1)	47 (20.3)		28 (32.6)	24 (18.3)	
Present of LVSI			0.211			0.069
Negative	85 (63.9)	163 (70.3)		49 (57.6)	92 (69.7)	
Positive	48 (36.1)	69 (29.7)		36 (42.4)	40 (30.3)	
Myometrial invasion			<0.001			< 0.001
< 50%	68 (51.1)	161 (69.4)		45 (52.9)	98 (74.2)	
≥ 50%	65 (48.9)	71 (30.6)		40 (47.1)	34 (25.8)	
Tumor grade			0.670			0.638
G1-G2	100 (75.2)	179 (77.2)		66 (77.6)	106 (80.3)	
G3	33 (24.8)	53 (22.8)		19 (22.4)	26 (19.7)	
Histology			0.836			0.794
Endometrioid	114 (85.7)	197 (84.9)		71 (83.5)	112 (84.8)	
Non-Endometrioid	19 (14.3)	35 (15.1)		14 (16.5)	20 (15.2)	
Serum Ca125			<0.001			0.097
≤ 35 U/ml	86 (64.7)	186 (80.2)		57 (67.1)	102 (77.3)	
> 35 U/ml	47 (35.3)	46 (19.8)		28 (32.9)	30 (22.7)	
ProMisE molecular			0.282			0.412
p53wt	53 (39.8)	102 (44.0)		35 (41.2)	67 (50.8)	
MMR-D	34 (25.6)	60 (25.9)		24 (28.2)	30 (22.7)	
POLE EDM	12 (9.0)	29 (12.4)		6 (7.1)	12 (9.1)	
p53-abn	34 (25.6)	41 (17.7)		20 (23.5)	23 (17.4)	
Adjuvant treatment			0.885			0.493
Follow-up	38 (28.6)	84 (36.2)		23 (27.1)	48 (36.4)	
Radiotherapy only	43 (32.3)	68 (29.3)		26 (30.6)	32 (24.2)	
Chemotherapy only	3 (2.3)	6 (2.6)		4 (4.7)	7 (5.3)	
Radio-chemotherapy	49 (36.8)	74 (31.9)		32 (37.6)	45 (34.1)	

Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphatic vessel space invasion; G1-G2, grade 1/2; G3, grade 3; POLE EDM, polymerase epsilon (POLE) exonuclease domain mutation; p53-abn, p53-abnormal; MMR-D, deficient mismatch repair; HALP, hemoglobin, albumin, lymphocyte, and platelet.

Survival analysis

To further validate the performance of the nomogram model in stratifying risk, patients from two cohorts were stratified into low-risk (total score ≤ 295.6 pts) and high-risk (total score > 295.6 pts) groups using the cutoff value of nomogram-generated scores for RFS (Figure S3). Kaplan-Meier curves demonstrated that patients classified as the high-risk had significantly worse RFS compared to those in the low-risk group ($P < 0.001$, Figure 6).

Discussion

Over the last couple of decades, the contributions of the immune system and inflammation to the development, progression, and treatment of cancer have garnered enormous attention and interest [24]. HALP, as a personalized oncology approach reflecting the overall nutrition-immune-inflammatory status, can be

utilized to predict the prognosis of cancer patients and offer valuable insights for treatment decisions. In this study, we included a total of 528 patients with endometrial cancer from four large medical institutions in southern and central-western China to investigate the prognostic significance of the pretreatment HALP score for survival outcomes. Our findings indicated that a low pretreatment HALP score serves as an unfavorable prognostic biomarker for cancer recurrence. Additionally, multiple clinicopathological data, preoperative blood parameters, and molecular classifications of endometrial cancer were obtained. The Cox proportional hazards method identified age, FIGO stage, tumor grade, LVSI, Ca125, ProMisE molecular classification, HALP score, and adjuvant treatment as independent prognostic factors for endometrial cancer recurrence. Furthermore, we developed a novel nomogram model to predict the RFS of operable endometrial cancer patients.




Figure 3. Characteristics in the nomogram model for predicting the probabilities of 1-, 2-, and 3-year RFS in patients with stage I-III endometrial cancer (A); ROC curves of the 1-, 2-, and 3-year RFS rates predicted by the model in both the training cohort (B) and the validation cohort (C).




Figure 4. Calibration curve of the nomogram model for predicting 1-, 2-, and 3-year RFS in the training set (A-C) and external validation set (D-F).




Figure 5. DCA curves of various risk stratification systems including the FIGO staging system, ProMisE molecular classification, and the established nomogram, for the prediction of 1-, 2-, and 3-year RFS in the training (A-C) and validation sets (D-F).




Figure 6. Kaplan-Meier curves of the low- and high-risk groups stratified by the predictive model. RFS curves in the training set (A) and the validation set (B).

HALP integrates routine hematological parameters, including hemoglobin, albumin, lymphocytes, and platelets to effectively reflect the individual's inflammation, nutrition, and immune status. It has been confirmed in clinical practice to predict the prognosis of ovarian cancer [25], hepatocellular carcinoma [25, 26], breast cancer [19], and esophageal cancer [27], etc. However, the mechanisms underlying HALP have not been fully elucidated, and the physiological and pathological

roles of these peripheral blood parameters may explain this to some extent. Hemoglobin serves as a crucial indicator of anemia, which is particularly common in cancer patients, especially in the advanced stages of the disease. Currently, it is believed that tumor cells produce a significant amount of pro-inflammatory cytokines, including IL-1 β and IL-6, as they adapt to the surrounding environment [28]. These cytokines not only intensify the inflammatory response but also disrupt the cell's iron utilization,

resulting in reduced erythropoietin production and decreased sensitivity of erythroid precursors to erythropoietin, ultimately affecting the generation and maturation of red blood cells [29]. The decrease in hemoglobin levels leads to anemia, resulting in tumor hypoxia and treatment resistance, which are closely associated with a worse prognosis in cancer patients [30]. An increasing amount of evidence highlights the link between nutritional status and malignant tumors [31]. Serum albumin, as an index for assessing nutritional status, is widely used in clinical practice due to its cost-effectiveness, non-invasiveness, and easy accessibility. Given that cancer is inherently a chronic wasting disease, patients frequently encounter malnutrition and hypoproteinemia [32]. Multiple studies have indicated that severe hypoproteinemia can lead to a poor prognosis in cancer patients [33, 34]. Elevated levels of lymphocytes in the peripheral blood directly reflect host anti-tumor immunity. Lymphocytes are the primary executors of host anti-tumor defense and immune surveillance. CD8⁺ T cells, as the primary effector cells in anti-tumor immune responses, have the ability to directly eliminate tumor cells through signaling pathways involving Fas and Fas ligand (FasL). Furthermore, these immune cells can secrete cytokines like interferon-gamma (IFN- γ) and tumor

necrosis factor-alpha (TNF- α), indirectly causing cell death or apoptosis, thereby improving patient prognosis [35]. Research has confirmed that there is an interaction between platelets and tumor cells, which can promote tumor growth by enhancing angiogenesis and inducing the proliferation of stromal cells. Additionally, platelets regulate the inflammatory response and alter the tumor microenvironment through both anti-inflammatory and pro-inflammatory mechanisms [36]. Pro-tumorigenic inflammation can reshape the tumor microenvironment towards a state that supports tumor growth and invasion by blocking anti-tumor immunity, and promoting cancer progression by exerting cytokines and signals on surrounding epithelial and stromal cells [37]. Some tumor cells, while not characterized by significant T cell infiltration or functional activation, may still exhibit pro-tumorigenic properties by upregulating inflammatory mediators and recruiting other immune cells such as macrophages, monocytes, neutrophils, etc. A substantial body of epidemiological studies also underscores the critical role of inflammation in promoting tumor initiation, growth, and progression [38]. Collectively, the HALP score can serve as a novel prognostic factor to assist in evaluating cancer patient prognosis [39].

Table 3. Factors associated with RFS in univariable and multivariable analysis

Variable	Univariable analysis		Multivariable analysis	
	HR (95% CI)	P value	HR (95% CI)	P value
Age at diagnosis (≥ 60 years vs < 60 years)	2.022 (1.170-3.494)	0.012	1.820 (1.005-3.293)	0.048
FIGO stage		< 0.001		0.113
I	Reference	-	Reference	-
II	1.789 (0.650-4.921)	0.260	1.298 (0.451-3.734)	0.629
III	7.697 (4.211-14.070)	< 0.001	2.309 (1.033-5.164)	0.042
Tumor grade (G3 vs G1-G2)	7.379 (4.267-12.760)	< 0.001	2.329 (1.082-5.016)	0.031
Histology (Non-Endometrioid vs Endometrioid)	4.604 (2.690-7.879)	< 0.001	1.073 (0.542-2.124)	0.841
LVSI (Positive vs Negative)	7.605 (4.151-13.935)	< 0.001	2.304 (1.022-5.195)	0.044
Myometrial invasion ($\geq 50\%$ vs $< 50\%$)	4.085 (2.331-7.159)	< 0.001	1.716 (0.924-3.186)	0.087
Serum Ca125 (> 35 U/ml vs ≤ 35 U/ml)	3.942 (2.330-6.667)	< 0.001	2.100 (1.135-3.885)	0.018
ProMisE molecular subgroup		< 0.001		0.067
p53wt	Reference	-	Reference	-
MMR-D	3.172 (1.464-6.871)	0.003	1.520 (0.673-3.434)	0.314
POLE EDM	0.370 (0.047-2.887)	0.343	0.388 (0.047-3.221)	0.381
p53abn	6.645 (3.214-13.736)	< 0.001	2.551 (1.093-5.954)	0.030
HALP score (Low HALP vs High HALP)	3.018 (1.765-5.161)	< 0.001	2.099 (1.182-3.728)	0.011
Adjuvant treatment (No vs Yes)	1.579 (0.863-2.892)	0.006	0.352 (0.160-0.774)	0.009

Abbreviations: HR, hazard ratio; CI, confidence interval; LVSI, lymphovascular space invasion; G1-G2, grade 1/2; G3, grade 3; POLE EDM, polymerase epsilon (POLE) exonuclease domain mutation; p53-wt, p53 wide-type; p53-abn, p53-abnormal; MMR-D, deficient mismatch repair; HALP, hemoglobin-albumin-lymphocyte-platelet.

Table 4. The predictive performance of diverse risk stratification models for predicting endometrial cancer recurrence

Risk stratification	Key predictors of the prediction model	C-index (95% CI)	
		Training set	Validation set
Model A [40]	A nomogram including age, surgical staging, histological grade, LVSI, FIGO staging.	0.801 (0.740-0.862)	0.786 (0.725-0.847)
Model B [41]	A risk stratification system based on systemic immune-inflammation index (SII).	0.638 (0.575-0.701)	0.602 (0.526-0.678)
Model C [42]	A nomogram model including age, Ca125, FIGO staging, LVSI, and P53.	0.810 (0.753-0.867)	0.796 (0.731-0.861)
Our model	A nomogram including age, FIGO staging, tumor grade, LVSI, serum Ca125, ProMisE molecular subgroup, HALP score, and adjuvant treatment.	0.875 (0.836-0.914)	0.859 (0.806-0.912)

Abbreviation: FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphatic vessel space invasion; SII, systemic immune-inflammation index; HALP, hemoglobin, albumin, lymphocyte, and platelet. **Note:** Comparing predictive performance among different models using the C-index, SII = platelet counts × neutrophil counts/lymphocyte counts.

In recent years, TCGA molecular subtyping has been shown to significant value in the prognostic evaluation of endometrial cancer and has been incorporated into the latest guidelines. However, due to the uneven development of regional healthcare, not all laboratories are currently able to perform NGS testing (TCGA molecular classification) for all endometrial cancer cases. During this transition phase, in situations with limited resources, priority may be given to immunohistochemical staining for at least 2 (PMS2 and MSH6) or preferably 4 (PMS2, MLH1, MSH6 and MSH2) of the MMR proteins, with immunostaining of p53 serving as a good surrogate for MSI-H and *TP53* mutation. Recently, scholars have proposed and confirmed the effectiveness of the ProMisE molecular classification system as an alternative method to NGS testing. Research has confirmed that the ProMisE classification system significantly reduces testing costs and technical barriers by detecting the exonuclease domain of *POLE* in exons 9-14, and IHC for MMR and p53 proteins. It has demonstrated a high level of consistency between diagnostic endometrial samples (biopsy or curettage) and whole uterine specimens. Consistent with a previous study of 452 women with endometrial cancer [10], we found that the ProMisE molecular classification was independently associated with RFS.

Accumulating evidence indicates that the prognosis and progression of endometrial cancer are associated not only with traditional clinicopathological variables but also with systemic inflammatory responses. Recent studies have reported a connection between cancer recurrence and the HALP score in stage I-III endometrial cancer. In recent years, there has been considerable interest in developing predictive models that utilize multiple markers rather than relying on single inflammatory markers. This retrospective study investigated the clinical significance of the HALP score in stage I-III endometrial cancer. By integrating traditional clinicopathological parameters, the HALP score, and ProMisE molecular subtyping, we constructed a nomogram model for a comprehensive evaluation of

patient prognosis. The model's performance was further evaluated and externally validated using Harrell's C-index, AUC value, calibration curve, and DCA curve. Additionally, the completeness of patient information in the dataset and the model's construction based on extensive data from multiple national medical institutions further enhanced the reliability and universality of the model. Furthermore, when compared with existing risk stratification systems, our model demonstrates more accurate predictions for RFS in endometrial cancer patients.

However, there remained some limitations in our study. Firstly, due to the retrospective nature of this study, many endometrial cancer patients in early clinical stages and low-risk categories were not recommended for genetic testing or *POLE* hotspot testing. This resulted in the loss of information regarding *POLE* variants and their exclusion from the study. Consequently, this may have led to an overall advanced FIGO stage and an increased prevalence of high-risk factors in the patient cohort of the present study. Moreover, the retrospective design introduces potential biases. Secondly, the sample size was relatively small, highlighting the need for future multi-center studies with expanded sample sizes. Additionally, given the significant differences in genetic backgrounds and lifestyles between Eastern and Western patients, this model may be more applicable to Eastern patients. Therefore, future research should further validate its applicability and predictive performance across diverse populations through prospective international multicenter clinical trials.

Conclusion

Our study demonstrates that HALP is an independent prognostic factor in endometrial cancer, which provides a nutrition-immune-inflammation perspective to understand the recurrence of the disease. Additionally, we constructed a nomogram for RFS by integrating traditional clinicopathological parameters, HALP score, and ProMisE molecular classification. This model will assist clinicians in

identifying high-risk patients and establishing individualized treatments.

Supplementary Material

Supplementary figures and tables.

<https://www.medsci.org/v22p3789s1.zip>

Acknowledgments

Funding

This work was supported by the Natural Science Foundation of Chongqing under Grant [No. CSTB2022NSCQ-MSX0071]; the Chongqing Municipal Science and Health Joint Medical Research Project under Grant [No. 2023MSXM116]; the Chongqing Municipal Health Appropriate Technology Promotion Program under Grant [No. 2022jstg018].

Data availability statement

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and informed consent

The research protocol was approved by the Institutional Review Board (IRB) of the First Affiliated Hospital of Chongqing Medical University (IRB number: 2024-01-32) & Army Medical University Southwest Hospital (IRB number: KY2024267) & Fujian Maternity and Child Health Care Hospital (IRB number: 2024-1-312) & the First Affiliated Hospital of Hengyang Medical School, University of South China (IRB number: 2024-IRB210). The study was conducted in accordance with the local legislation and institutional requirements. Written informed consent was obtained from the patients for their anonymized information to be published in this study.

Author contributions

Yunfeng Zheng: Methodology, Data curation, Formal analysis, Writing-Original draft preparation, Writing - Review & Editing; Chenfan Tian: Data curation, Writing-Review & Editing; Gaohua Liu, Xixi Wu: Data curation, Formal analysis; Langting Xie, Ran Hu, Fan Yang: Data curation, Supervision; Xiaoxiao Luo, Rui Yuan: Conceptualization, Methodology, Writing-Review & Editing; All authors critically reviewed the paper and approved the final version.

Competing Interests

The authors have declared that no competing interest exists.

References

- Gu B, Shang X, Yan M, et al. Variations in incidence and mortality rates of endometrial cancer at the global, regional, and national levels, 1990-2019. *Gynecol Oncol.* 2021; 161: 573-80.
- Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. *Neuro Oncol.* 2021; 23: 1231-51.
- Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. *Chin Med J (Engl).* 2022; 135: 584-90.
- Makker V, MacKay H, Ray-Coquard I, et al. Endometrial cancer. *Nat Rev Dis Primers.* 2021; 7: 88.
- Ørtoft G, Lausten-Thomsen L, Høgdall C, et al. Lymph-vascular space invasion (LVSI) as a strong and independent predictor for non-locoregional recurrences in endometrial cancer: a Danish Gynecological Cancer Group Study. *J Gynecol Oncol.* 2019; 30: e84.
- Zheng Y, Jiang P, Tu Y, et al. Incidence, risk factors, and a prognostic nomogram for distant metastasis in endometrial cancer: A SEER-based study. *Int J Gynaecol Obstet.* 2024; 165: 655-65.
- Bokhman JV. Two pathogenetic types of endometrial carcinoma. *Gynecol Oncol.* 1983; 15: 10-7.
- Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. *Nature.* 2013; 497: 67-73.
- Stelloo E, Bosse T, Nout RA, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative. *Mod Pathol.* 2015; 28: 836-44.
- Kommoss S, McConechy MK, Kommoss F, et al. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series. *Ann Oncol.* 2018; 29: 1180-8.
- So YK, Kim Z, Cheong TY, et al. Detection of Cancer Recurrence Using Systemic Inflammatory Markers and Machine Learning after Concurrent Chemoradiotherapy for Head and Neck Cancers. *Cancers (Basel).* 2023; 15: 3540.
- Savioli F, Morrow ES, Dolan RD, et al. Prognostic role of preoperative circulating systemic inflammatory response markers in primary breast cancer: meta-analysis. *Br J Surg.* 2022; 109: 1206-15.
- Hu B, Yang XR, Xu Y, et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. *Clin Cancer Res.* 2014; 20: 6212-22.
- Nøst TH, Alcalá K, Urbarova I, et al. Systemic inflammation markers and cancer incidence in the UK Biobank. *Eur J Epidemiol.* 2021; 36: 841-8.
- Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. *J Immunother Cancer.* 2018; 6: 74.
- Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst.* 2014; 106: dju124.
- Chen L, Bai P, Kong X, et al. Prognostic Nutritional Index (PNI) in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy as a Useful Prognostic Indicator. *Front Cell Dev Biol.* 2021; 9: 656741.
- Chen XL, Xue L, Wang W, et al. Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study. *Oncotarget.* 2015; 6: 41370-82.
- Jiang T, Sun H, Xue S, et al. Prognostic significance of hemoglobin, albumin, lymphocyte, and platelet (HALP) score in breast cancer: a propensity score-matching study. *Cancer Cell Int.* 2024; 24: 230.
- Zheng Y, Shen Q, Yang F, et al. A nomogram model to predict recurrence of early-onset endometrial cancer after resection based on clinical parameters and immunohistochemical markers: a multi-institutional study. *Front Oncol.* 2024; 14: 1442489.
- Talhok A, Hoang LN, McConechy MK, et al. Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. *Gynecol Oncol.* 2016; 143: 46-53.
- Talhok A, McConechy MK, Leung S, et al. A clinically applicable molecular-based classification for endometrial cancers. *Br J Cancer.* 2015; 113: 299-310.
- McConechy MK, Talhok A, Leung S, et al. Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis. *Clin Cancer Res.* 2016; 22: 2865-73.
- Zheng Y, Yang F, Wu J. LRP1B mutation is associated with lymph node metastasis in endometrial carcinoma: A clinical next-generation sequencing study. *Int J Biol Markers.* 2024; 3936155241304433.
- Atjimakul T, Saeab N, Tunthanathip T, et al. Significance of Pretreatment Hemoglobin-Albumin-Lymphocyte-Platelet Index for the Prediction of Suboptimal Surgery in Epithelial Ovarian Cancer. *World J Oncol.* 2024; 15: 268-78.
- Liu X, Qiu Z, Ndhlovu E, et al. Establishing and Externally Validating a Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) Score-Based Nomogram for Predicting Early Recurrence in BCLC Stage 0/A Hepatocellular Carcinoma Patients After Radical Liver Resection: A Multi-Center Study. *J Hepatocell Carcinoma.* 2024; 11: 1127-41.
- Shi Y, Shen G, Zeng Y, et al. Predictive values of the hemoglobin, albumin, lymphocyte and platelet score (HALP) and the modified -Gustave Roussy

- immune score for esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy. *Int Immunopharmacol.* 2023; 123: 110773.
28. Chung MH, Chang WP. Correlation between hemoglobin levels and depression in late-stage cancer patients with irritability as mediating variable. *Eur J Oncol Nurs.* 2023; 67: 102414.
 29. O'Higgins CM, Brady B, O'Connor B, et al. The pathophysiology of cancer-related fatigue: current controversies. *Support Care Cancer.* 2018; 26: 3353-64.
 30. Belcher DA, Ju JA, Baek JH, et al. The quaternary state of polymerized human hemoglobin regulates oxygenation of breast cancer solid tumors: A theoretical and experimental study. *PLoS One.* 2018; 13: e0191275.
 31. Zitvogel L, Pietrocola F, Kroemer G. Nutrition, inflammation and cancer. *Nat Immunol.* 2017; 18: 843-50.
 32. Chen L, Kong X, Yan C, et al. The Research Progress on the Prognostic Value of the Common Hematological Parameters in Peripheral Venous Blood in Breast Cancer. *Onco Targets Ther.* 2020; 13: 1397-412.
 33. Wang MD, Duan FF, Hua X, et al. A Novel Albumin-Related Nutrition Biomarker Predicts Breast Cancer Prognosis in Neoadjuvant Chemotherapy: A Two-Center Cohort Study. *Nutrients.* 2023; 15: 4292.
 34. Oñate-Ocaña LF, Aiello-Crocifoglio V, Gallardo-Rincón D, et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. *Ann Surg Oncol.* 2007; 14: 381-9.
 35. van der Leun AM, Thommen DS, Schumacher TN. CD8(+) T cell states in human cancer: insights from single-cell analysis. *Nat Rev Cancer.* 2020; 20: 218-32.
 36. Franco AT, Corken A, Ware J. Platelets at the interface of thrombosis, inflammation, and cancer. *Blood.* 2015; 126: 582-8.
 37. Li S, Lu Z, Wu S, et al. The dynamic role of platelets in cancer progression and their therapeutic implications. *Nat Rev Cancer.* 2024; 24: 72-87.
 38. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. *Lancet.* 2012; 379: 1591-601.
 39. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. *Immunity.* 2019; 51: 27-41.
 40. Ouldamer L, Bendifallah S, Body G, et al. Predicting poor prognosis recurrence in women with endometrial cancer: a nomogram developed by the FRANCOGYN study group. *Br J Cancer.* 2016; 115: 1296-303.
 41. Matsubara S, Mabuchi S, Takeda Y, et al. Prognostic value of pre-treatment systemic immune-inflammation index in patients with endometrial cancer. *PLoS One.* 2021; 16: e0248871.
 42. Li Y, Hou X, Chen W, et al. Development and validation of a nomogram for predicting recurrence-free survival in endometrial cancer: a multicenter study. *Sci Rep.* 2023; 13: 20270.

Author Biography

Dr. Yunfeng Zheng received his M.D. degree from The First Clinical College of Chongqing Medical University. He is currently working at the Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University. He has authored or co-authored more than 10 peer-reviewed articles, including *World J Surg Oncol*, *J Inflamm Res*, and *Int J Gynaecol Obstet*. Currently, his research focuses on integrating multi-omics data, including genomics, transcriptomics, and proteomics, to advance precision medicine; regulating the tumor microenvironment to enhance the immune system's recognition of and attack on tumors; and exploring the molecular mechanisms by which tumor cells evade immune surveillance.